Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 78 clinical-stage projects, 32 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.
Changes that occurred in our R&D pipeline are detailed in our quarterly earnings press release, issued on 25 October 2024.
Search for a Specific a Clinical-Stage Project
Therapeutic Area
Immunology & Inflammation
Name
SAR444336
Phase
Description
Indication
Inflammatory indication
Inflammatory indication
Therapeutic Area
Immunology & Inflammation
Name
SAR445399
Phase
Description
Indication
Inflammatory indication
Inflammatory indication
Therapeutic Area
Immunology & Inflammation
Name
SAR445611
Phase
Description
Indication
Inflammatory indication
Inflammatory indication
Therapeutic Area
Immunology & Inflammation
Name
SAR446422
Phase
Description
Indication
Inflammatory indication
Inflammatory indication
Therapeutic Area
Immunology & Inflammation
Name
amlitelimab
Phase
Description
Indication
Celiac disease
Celiac disease
Therapeutic Area
Immunology & Inflammation
Name
amlitelimab
Phase
Description
Indication
Systemic sclerosis
Systemic sclerosis
Therapeutic Area
Immunology & Inflammation
Name
amlitelimab
Phase
Description
Indication
Alopecia areata
Alopecia areata
Therapeutic Area
Immunology & Inflammation
Name
amlitelimab
Phase
Description
Indication
Hidradenitis suppurativa
Hidradenitis suppurativa
Therapeutic Area
Immunology & Inflammation
Name
amlitelimab
Phase
Description
Indication
Asthma
Asthma
Therapeutic Area
Immunology & Inflammation
Name
Dupixent
Phase
Description
Indication
Ulcerative colitis
Ulcerative colitis
Therapeutic Area
Immunology & Inflammation
Name
duvakitug
Phase
Description
Indication
Crohn's disease
Crohn's disease
Therapeutic Area
Immunology & Inflammation
Name
duvakitug
Phase
Description
Indication
Ulcerative colitis
Ulcerative colitis
Therapeutic Area
Immunology & Inflammation
Name
eclitasertib
Phase
Description
Indication
Ulcerative colitis
Ulcerative colitis
Therapeutic Area
Immunology & Inflammation
Name
frexalimab
Phase
Description
Indication
Type 1 diabetes
Type 1 diabetes
Therapeutic Area
Immunology & Inflammation
Name
frexalimab
Phase
Description
Indication
Systemic lupus erythematosus
Systemic lupus erythematosus
Therapeutic Area
Immunology & Inflammation
Name
itepekimab
Phase
Description
Indication
Bronchiectasis
Bronchiectasis
Therapeutic Area
Immunology & Inflammation
Name
lunsekimig
Phase
Description
Indication
Chronic rhinosinusitis with nasal polyps
Chronic rhinosinusitis with nasal polyps
Therapeutic Area
Immunology & Inflammation
Name
lunsekimig
Phase
Description
Indication
Asthma
Asthma
Therapeutic Area
Immunology & Inflammation
Name
riliprubart
Phase
Description
Indication
Antibody-mediated rejection
Antibody-mediated rejection
Therapeutic Area
Immunology & Inflammation
Name
rilzabrutinib
Phase
Description
Indication
Chronic spontaneous urticaria
Chronic spontaneous urticaria
Therapeutic Area
Immunology & Inflammation
Name
rilzabrutinib
Phase
Description
Indication
Asthma
Asthma
Therapeutic Area
Immunology & Inflammation
Name
rilzabrutinib
Phase
Description
Indication
IgG4-related disease
IgG4-related disease
Therapeutic Area
Immunology & Inflammation
Name
SAR441566
Phase
Description
Indication
Rheumatoid arthritis
Rheumatoid arthritis
Therapeutic Area
Immunology & Inflammation
Name
SAR441566
Phase
Description
Indication
Psoriasis
Psoriasis
Therapeutic Area
Immunology & Inflammation
Name
SAR442970
Phase
Description
Indication
Hidradenitis suppurativa
Hidradenitis suppurativa
Therapeutic Area
Immunology & Inflammation
Name
SAR444656
Phase
Description
Indication
Hidradenitis suppurativa
Hidradenitis suppurativa
Therapeutic Area
Immunology & Inflammation
Name
SAR444656
Phase
Description
Indication
Atopic dermatitis
Atopic dermatitis
Therapeutic Area
Immunology & Inflammation
Name
amlitelimab
Phase
Description
Indication
Atopic dermatitis
Atopic dermatitis
Therapeutic Area
Immunology & Inflammation
Name
Dupixent
Phase
Description
Indication
Chronic spontaneous urticaria (US)
Chronic spontaneous urticaria (US)
Therapeutic Area
Immunology & Inflammation
Name
Dupixent
Phase
Description
Indication
Eosinophilic gastritis
Eosinophilic gastritis
Therapeutic Area
Immunology & Inflammation
Name
Dupixent
Phase
Description
Indication
Bullous pemphigoid
Bullous pemphigoid
Therapeutic Area
Immunology & Inflammation
Name
Dupixent
Phase
Description
Indication
Chronic pruritis of unknown origin
Chronic pruritis of unknown origin
Therapeutic Area
Immunology & Inflammation
Name
itepekimab
Phase
Description
Indication
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
Therapeutic Area
Immunology & Inflammation
Name
Rezurock
Phase
Description
Indication
1L chronic graft versus host disease
1L chronic graft versus host disease
Therapeutic Area
Immunology & Inflammation
Name
Rezurock
Phase
Description
Indication
Chronic lung allograft dysfunction
Chronic lung allograft dysfunction
Therapeutic Area
Immunology & Inflammation
Name
Tzield
Phase
Description
Indication
Type 1 diabetes
Type 1 diabetes
Therapeutic Area
Immunology & Inflammation
Name
Dupixent
Phase
Description
Indication
Chronic obstructive pulmonary disease (JP)
Chronic obstructive pulmonary disease (JP)
Therapeutic Area
Immunology & Inflammation
Name
Dupixent
Phase
Description
Indication
Chronic spontaneous urticaria (EU)
Chronic spontaneous urticaria (EU)
Therapeutic Area
Neurology
Name
SAR446159
Phase
Description
Indication
Parkinson's disease
Parkinson's disease
Therapeutic Area
Neurology
Name
frexalimab
Phase
Description
Indication
Non-relapsing secondary progressive MS
Non-relapsing secondary progressive MS
Therapeutic Area
Neurology
Name
frexalimab
Phase
Description
Indication
Relapsing multiple sclerosis
Relapsing multiple sclerosis
Therapeutic Area
Neurology
Name
riliprubart
Phase
Description
Indication
IVIg-treated CIDP
IVIg-treated CIDP
Therapeutic Area
Neurology
Name
riliprubart
Phase
Description
Indication
SOC-refractory CIDP
SOC-refractory CIDP
Therapeutic Area
Neurology
Name
tolebrutinib
Phase
Description
Indication
Non-relapsing secondary progressive MS
Non-relapsing secondary progressive MS
Therapeutic Area
Neurology
Name
tolebrutinib
Phase
Description
Indication
Primary progressive MS
Primary progressive MS
Therapeutic Area
Neurology
Name
tolebrutinib
Phase
Description
Indication
Relapsing multiple sclerosis
Relapsing multiple sclerosis
Therapeutic Area
Oncology
Name
pegenzileukin
Phase
Description
Indication
Cancer, in combination
Cancer, in combination
Therapeutic Area
Oncology
Name
SAR444200
Phase
Description
Indication
Solid tumors
Solid tumors
Therapeutic Area
Oncology
Name
SAR444881
Phase
Description
Indication
Solid tumors
Solid tumors
Therapeutic Area
Oncology
Name
SAR445514
Phase
Description
Indication
Relapsed/refractory multiple myeloma
Relapsed/refractory multiple myeloma
Therapeutic Area
Oncology
Name
SAR445877
Phase
Description
Indication
Solid tumors
Solid tumors
Therapeutic Area
Oncology
Name
SAR445953
Phase
Description
Indication
Colorectal cancer
Colorectal cancer
Therapeutic Area
Oncology
Name
SAR443579
Phase
Description
Indication
Acute myeloid leukemia
Acute myeloid leukemia
Therapeutic Area
Oncology
Name
Sarclisa
Phase
Description
Indication
Multiple myeloma, relapsed/refractory
Multiple myeloma, relapsed/refractory
Therapeutic Area
Oncology
Name
Sarclisa
Phase
Description
Indication
Multiple myeloma, 1L TE (IsKia)
Multiple myeloma, 1L TE (IsKia)
Therapeutic Area
Oncology
Name
Sarclisa
Phase
Description
Indication
Multiple myeloma, relapsed/refractory (IRAKLIA)
Multiple myeloma, relapsed/refractory (IRAKLIA)
Therapeutic Area
Oncology
Name
Sarclisa
Phase
Description
Indication
Smoldering multiple myeloma (ITHACA)
Smoldering multiple myeloma (ITHACA)
Therapeutic Area
Oncology
Name
Sarclisa
Phase
Description
Indication
Multiple myeloma, 1L TE (HD7)
Multiple myeloma, 1L TE (HD7)
Therapeutic Area
Oncology
Name
Sarclisa
Phase
Description
Indication
Myélome multiple, 1L TI (IMROZ) (EU, JP, CN)
Myélome multiple, 1L TI (IMROZ) (EU, JP, CN)
Therapeutic Area
Rare Diseases
Name
rilzabrutinib
Phase
Description
Indication
Warm autoimmune hemolytic anemia
Warm autoimmune hemolytic anemia
Therapeutic Area
Rare Diseases
Name
SAR447537
Phase
Description
Indication
Alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin deficiency
Therapeutic Area
Rare Diseases
Name
Nexviazyme
Phase
Description
Indication
Pompe disease, infantile onset (US)
Pompe disease, infantile onset (US)
Therapeutic Area
Rare Diseases
Name
rilzabrutinib
Phase
Description
Indication
Immune thrombocytopenia
Immune thrombocytopenia
Therapeutic Area
Rare Diseases
Name
venglustat
Phase
Description
Indication
Fabry disease
Fabry disease
Therapeutic Area
Rare Diseases
Name
venglustat
Phase
Description
Indication
Gaucher disease type 3
Gaucher disease type 3
Therapeutic Area
Rare Diseases
Name
fitusiran
Phase
Description
Indication
Hemophilia A and B (US, CN)
Hemophilia A and B (US, CN)
Therapeutic Area
Vaccines
Name
SP0237
Phase
Description
Indication
Flu
Flu
Therapeutic Area
Vaccines
Name
SP0256
Phase
Description
Indication
hMPV/RSV older adults
hMPV/RSV older adults
Therapeutic Area
Vaccines
Name
SP0268
Phase
Description
Indication
Acne
Acne
Therapeutic Area
Vaccines
Name
Fluzone HD
Phase
Description
Indication
Flu, pediatric
Flu, pediatric
Therapeutic Area
Vaccines
Name
SP0202
Phase
Description
Indication
Pneumococcal disease
Pneumococcal disease
Therapeutic Area
Vaccines
Name
SP0218
Phase
Description
Indication
Yellow fever
Yellow fever
Therapeutic Area
Vaccines
Name
SP0230
Phase
Description
Indication
Meningitis
Meningitis
Therapeutic Area
Vaccines
Name
SP0256
Phase
Description
Indication
RSV older adult
RSV older adult
Therapeutic Area
Vaccines
Name
SP0087
Phase
Description
Indication
Rabies
Rabies
Therapeutic Area
Vaccines
Name
SP0125
Phase
Description
Indication
Respiratory syncytial virus (toddler)
Respiratory syncytial virus (toddler)
Therapeutic Area
Vaccines
Name
SP0282
Phase
Description
Indication
E. coli sepsis
E. coli sepsis
Therapeutic Area
Vaccines
Name
MenQuadfi
Phase
Description
Indication
Meningitis six weeks+ (US)
Meningitis six weeks+ (US)